Xencor Stock

Xencor EBIT

The EBIT of Xencor (XNCR) as of Jul 27, 2026 is -85.02 M USD. In the previous year, EBIT was -230.21 M USD — a change of -63.07% (higher).

EBIT

-85.02 MUSD

YoY

-63.07%

Last updated:

In 2026, Xencor's EBIT was -85.02 M USD, a -63.07% increase from the -230.21 M USD EBIT recorded in the previous year.

The Xencor EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2020
-76.80 base
Jan 1, 2021
43.77 base
Jan 1, 2022
-82.47 base
Jan 1, 2023
-138.64 base
Jan 1, 2024
-230.21 base
Jan 1, 2025
-85.02 base
Jan 1, 2026 (e)
-218.21 base
Jan 1, 2027 (e)
-204.83 base
YEAREBIT (M USD)
2027 est -204.83
2026 est -218.21
2025 -85.02
2024 -230.21
2023 -138.64
2022 -82.47
2021 43.77
2020 -76.80
2019 13.82
2018 -79.37
2017 -53.56
2016 22.54
2015 -18.34
2014 -16.46
2013 -10.52
2012 -6.23
2011 -9.45
Access this data via the Eulerpool API

Xencor Revenue

Xencor Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
122.69 M USD
-76.80 M USD
-63.54 M USD
Jan 1, 2021
275.11 M USD
43.77 M USD
82.63 M USD
Jan 1, 2022
164.58 M USD
-82.47 M USD
-55.18 M USD
Jan 1, 2023
168.34 M USD
-138.64 M USD
-126.09 M USD
Jan 1, 2024
110.49 M USD
-230.21 M USD
-232.62 M USD
Jan 1, 2025
125.58 M USD
-85.02 M USD
-91.92 M USD
Jan 1, 2026 (e)
70.58 M USD
-218.21 M USD
-287.50 M USD
Jan 1, 2027 (e)
110.45 M USD
-204.83 M USD
-253.34 M USD

Xencor Margins

Xencor stock margins

The Xencor margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Xencor. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Xencor.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-62.59 %
-51.79 %
Jan 1, 2021
100.00 %
15.91 %
30.04 %
Jan 1, 2022
100.00 %
-50.11 %
-33.53 %
Jan 1, 2023
-50.65 %
-82.36 %
-74.90 %
Jan 1, 2024
-106.06 %
-208.35 %
-210.53 %
Jan 1, 2025
91.63 %
-67.70 %
-73.20 %
Jan 1, 2026 (e)
91.63 %
-309.15 %
-407.32 %
Jan 1, 2027 (e)
91.63 %
-185.46 %
-229.38 %

Xencor Stock analysis

What does Xencor do? The company Xencor Inc was founded in 1997 and has since become a significant biotechnology company specializing in the development of therapeutic proteins. Xencor's goal is to develop innovative and tailored therapies for the treatment of serious diseases such as cancer and autoimmune diseases. The company is headquartered in Monrovia, California, and employs a growing number of scientists, engineers, and other professionals specialized in the development of new themes and products. Xencor has acquired a variety of patents over the years to protect its intellectual property. Its business model is based on the development of new therapeutics through its proprietary XmAb technology platform, which enables the production of highly specific polyclonal antibodies that can improve the efficiency and safety of disease treatments. Xencor has divided its business activities into various divisions, including the development of immuno-oncology products, autoimmune therapies, and new methods for the therapy of inflammatory bowel diseases. The company has developed a wide range of products, including a new class of therapeutic antibodies that mobilize and strengthen patients' own immune system to fight cancer cells. By combining these antibodies with other therapies, the effectiveness of the treatment can be further increased. In the autoimmune diseases division, Xencor has developed new therapeutics to better regulate patients' immune system and treat dangerous autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, or lupus. Another focus of the company is the development of therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease. By developing specific antibodies involved in the inflammatory processes in the intestine, Xencor can contribute to improving the treatment of these conditions. Xencor aims to accelerate the development of new therapeutics while improving their efficacy and safety. With the help of its proprietary XmAb technology platform, the company is able to develop new drugs faster and more effectively than conventional methods. Through the combination of technology, research and development, and a high level of commitment, Xencor pursues its vision and has successfully established itself as one of the leading companies in the biotechnology industry. Xencor is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Xencor's EBIT

Xencor's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Xencor's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Xencor's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Xencor’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Xencor stock

EBIT of Xencor is -85.02 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Xencor

All Key Metrics — Xencor